Poly[oxy(1-oxo-1,6-hexanediyl)], I+/-,I+/-a(2)-(oxydi-2,1-ethanediyl)bis[I-[(1-oxo-2-propen-1-yl)oxy]- | 60251-19-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Poly[oxy(1-oxo-1,6-hexanediyl)], I+/-,I+/-a(2)-(oxydi-2,1-ethanediyl)bis[I-[(1-oxo-2-propen-1-yl)oxy]-
• 英文别名: 2-[2-(6-prop-2-enoyloxyhexanoyloxy)ethoxy]ethyl 6-prop-2-enoyloxyhexanoate
• CAS: 60251-19-6
• 化学式: C₂₂H₃₄O₉
• 分子量: 442.5
• InChiKey: DUQNDYKOASNMBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  31
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  114
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Readily shapeable xerogels having controllably delayed swelling properties
  申请人：Huh Moo Kang

  公开号：US20070031499A1

  公开（公告）日：2007-02-08

  Hydrogels are described which have delayed swelling properties. A hydrogel is formed by reacting a hydrophilic monomer, a first crosslinker, and a second crosslinker. The first crosslinker defines the volume expansion of the hydrogel in an aqueous environment, and the second crosslinker, which is biodegradable, can modulate the swelling rate of the hydrogel in aqueous solution. In its dry state, the hydrogel (xerogel) is flexible and elastic. It can also be cut with a knife or scissors, or molded or shaped by hand. The ready shapeability of the xerogel by trimming or compression affords a superior hydrogel for medical applications.

  描述了具有延迟膨胀特性的水凝胶。水凝胶是通过反应亲水性单体、第一交联剂和第二交联剂形成的。第一交联剂定义了水凝胶在水环境中的体积膨胀，而第二交联剂，它是可生物降解的，可以调节水溶液中水凝胶的膨胀速率。在干燥状态下，水凝胶（干凝胶）是柔软和有弹性的。它也可以用刀或剪刀切割，或者通过手工塑造或成形。通过修剪或压缩的便捷成形性为医疗应用提供了优越的水凝胶。
• NANOCOMPOSITES OF GOLD AND POLYMERS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20140294909A1

  公开（公告）日：2014-10-02

  A layer-by-layer (LbL) system, which alternately ionically complexes anionic AuNPs to two unique cationic polymers (disulfide-reducible and hydrolytically degradable) and two anionic nucleic acids, is disclosed.

  本文介绍了一种逐层（LbL）系统，该系统交替离子复合两种独特的阳离子聚合物（二硫键可还原和水解降解）和两种阴离子核酸到阴离子AuNPs上。
• PEPTIDE/PARTICLE DELIVERY SYSTEMS
  申请人：Green Jordan Jamieson

  公开号：US20120114759A1

  公开（公告）日：2012-05-10

  Polymeric nanoparticles, microparticles, and gels for delivering cargo, e.g., a therapeutic agent, such as a peptide, to a target, e.g., a cell, and their use for treating diseases, including angiogenesis-dependent diseases, such as age-related macular degeneration and cancer, are disclosed. Methods for formulating, stabilizing, and administering single peptides or combinations of peptides via polymeric particle and gel delivery systems also are disclosed.
• Multicomponent Degradable Cationic Polymers
  申请人：Green Jordan J.

  公开号：US20120128782A1

  公开（公告）日：2012-05-24

  Degradable polymers were synthesized that self-assemble with DNA to form particles that are effective for gene delivery. Small changes to polymer synthesis conditions, particle formulation conditions, and polymer structure provides significant changes to efficacy in a cell-type dependent manner. Polymers presented here are more effective than commercially available materials, such as LIPOFECTAMINE 2000 ™, FUGENE®, or polyethylenimine (PEI), for gene delivery to cancerous fibroblasts or human primary fibroblasts. The presently disclosed materials may be useful for cancer therapeutics and regenerative medicine.
• Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20150273071A1

  公开（公告）日：2015-10-01

  Degradable polymers were synthesized that self-assemble with nucleic acids, proteins, hydrophobic drugs, and other small molecules to form particles that are effective for delivery into a cell, tissue and/or organism either in vitro or in vivo. The presently disclosed polymers demonstrate differential cell-type specificity, an ability to promote endosomal escape to protect the cargos from degradation and enhance delivery to the cytoplasm, and/or bioreducibility, which enables triggered intracellular drug release to be tuned to promote optimal delivery to the target cell type. The presently disclosed materials may be used to treat a wide variety of conditions or diseases, such as cancer, cardiovascular diseases, infectious diseases, and ophthalmic diseases.